AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.054

+0.0011.89%

Volume:4.42M

Turnover:230.94K

Market Cap:79.58M

PE:-0.94

High:0.054

Open:0.053

Low:0.051

Close:0.053

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.88

T/O Rate:0.36%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.057

EPS(LYR):-0.042

ROE:-61.85%

ROA:-32.10%

PB:0.80

PE(LYR):-1.28

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+2.85%

Capital Flow

Inflow:

Outflow:

News

Immutep Says Eftisarc-neo Phase II Eposter on Efti Hrqol in Soft Tissue Sarcoma Accepted for ESMO 2026

Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%

MT Newswires Live

Immutep Provides Clinical Update in 1st Line Nsclc: Positive Mature Overall Survival Data from Insight-003 and Update from Tacti-004

THOMSON REUTERS

Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/IMM.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.054,"timestamp":1787638320000,"preClose":0.053,"halted":0,"volume":4418485,"delay":0,"changeRate":0.018867924528301903,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.057294,"marketStatus":"Not Yet Opened","change":0.001,"latestTime":"08-25 16:12:00 AEST","open":0.053,"high":0.054,"low":0.051,"amount":230940,"amplitude":0.056604,"askPrice":0.054,"askSize":1352966,"bidPrice":0.052,"bidSize":379541,"shortable":3,"etf":0,"ttmEps":-0.057294,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.053,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.882611,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.053,"auctionPrice":0.052,"auctionVolume":406378,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638203503}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-32.10%","roe":"-61.85%","lyrEps":-0.042199,"volumeRatio":0.882611,"shares":1473721306,"dividePrice":0,"high":0.054,"amplitude":0.056604,"preClose":0.053,"low":0.051,"week52Low":0.028,"pbRate":"0.80","psRate":"10.04","week52High":0.47,"institutionHeld":0,"latestPrice":0.054,"committee":-0.561859,"eps":-0.057294,"divideRate":0,"volume":4418485,"delay":0,"ttmEps":-0.057294,"open":0.053,"prevYearClose":0.415,"prevWeekClose":0.053,"prevMonthClose":0.046,"prevQuarterClose":0.053,"fiveDayClose":0.053,"twentyDayClose":0.047,"sixtyDayClose":0.053,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653084916","title":"Immutep Says Eftisarc-neo Phase II Eposter on Efti Hrqol in Soft Tissue Sarcoma Accepted for ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653084916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653084916?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:05","pubTimestamp":1784894709,"startTime":"0","endTime":"0","summary":"Immutep says EFTISARC-NEO Phase II ePoster on efti HRQoL in soft tissue sarcoma accepted for ESMO 2026Immutep flagged an accepted ESMO Congress 2026 ePoster from the Phase II EFTISARC-NEO trial of eft","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL3Nl1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651126444","title":"Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651126444","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651126444?lang=en_us&edition=fundamental","pubTime":"2026-07-14 11:25","pubTimestamp":1783999558,"startTime":"0","endTime":"0","summary":"Immutep  obtained a fourth patent from the US Patent and Trademark Office related to its cancer treatments, according to a Tuesday filing with the Australian bourse.The new patent, which covers methods to treat cancer by administering eftilagimod alfa in combination with PD-1 pathway inhibitors, has an expiry date of Jan. 20, 2036, per the filing.The company is evaluating eftilagimod alfa in a variety of solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer.Immutep shares fell nearly 4% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651811966","title":"Immutep Provides Clinical Update in 1st Line Nsclc: Positive Mature Overall Survival Data from Insight-003 and Update from Tacti-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2651811966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651811966?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651196131","title":"Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651196131?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":21,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMM.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.0285}]}}